Screener
Ionis Pharmaceuticals IONS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Net income (loss) | $$(114,646) | $123,551 | $(207,174) | (23,387) |
| Unrealized gains (losses) on debt securities, net of tax | (2,824) | 367 | (8,428) | 1,997 |
| Currency translation adjustment | (50) | 595 | (188) | 827 |
| Comprehensive income (loss) | $$(117,520) | $124,513 | $(215,790) | (20,563) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Ionis Pharmaceuticals (IONS) reported comprehensive income (loss), net of tax, attributable to parent of -$117.52M in Q2 2026.
- How has Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 194.4% year-over-year, from $124.51M to -$117.52M.
- What is the long-term trend for Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 4.9% compound annual growth rate (CAGR), from -$341.45M to -$375.86M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- Represents the total change in equity from non-owner sources, including net income plus other comprehensive income items like unrealized gains on securities and foreign currency adjustments. It provides a broader view of financial performance than net income alone.
Ask your AI about Ionis Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude